The short version
Oruka Therapeutics (ORKA) rose about 12% on Monday, to roughly $89, after mid-stage results for its psoriasis treatment.
The result: in a 187-patient Phase 2b trial, 61% of patients on the high dose had completely clear skin at Week 16, against 0% on placebo. A further measure, 90% improvement, was reached by 86%.
Safety looked clean: 39% of high-dose patients reported a treatment-emergent side effect, against 43% on placebo, and none were serious.
The interesting part is the dosing. The company is designing its next trial around once-yearly maintenance. Existing treatments in this class are typically given every few weeks.
And the contrast is the lesson. Last week a cancer vaccine hit its target and Moderna fell 18%. This week a psoriasis drug hit its target and Oruka rose 12%. Same kind of news, opposite reactions, and the reason has nothing to do with the medicine.
Stated clearly: this treatment is not approved and not available. This is an article about share prices, not medical advice, and nobody should draw conclusions about their own care from it.
Explore global stocks and ETFs from $1 on Nemo.money — zero commission, and uninvested cash earns 6% AER interest, paid daily in USD.
What the trial actually showed
The study: EVERLAST-B, a Phase 2b trial in 187 patients with moderate-to-severe plaque psoriasis, testing three dose levels of ORKA-001 against placebo.
The headline measures at Week 16:
- 🎯 Complete skin clearance (PASI 100): 61% on the high dose, against 0% on placebo
- 📊 90% improvement (PASI 90): 86% on the high dose
- 📈 Results rose with dose, 43% and 44% complete clearance on the two lower doses
- 🩺 Side effects: 39% of high-dose patients reported one, against 43% on placebo. None were serious, and no injection-site reactions were reported
What those measures mean. PASI is a standard scoring system for psoriasis severity. PASI 100 means the score fell to zero at that point in the trial, which is described as complete skin clearance. It is a measurement at Week 16 in a clinical study, not a statement about any individual's long-term outcome.
Why the dosing matters more than the percentage
Most psoriasis biologics are injected every few weeks. Oruka's high dose was given at Week 0 and Week 4, and the company's planned Phase 3 design targets maintenance dosing once a year.
If that holds, the product's advantage isn't only how well it works, it's how rarely patients would need it. For a chronic condition managed over decades, that changes the experience of treatment and the economics around it.
The company's framing, attributed to them: the chief medical officer described a remarkable profile with potential for dosing once to twice per year, and an investigator quoted in the release said the results suggest it is likely the most effective medicine of its type so far. Those are their characterisations, made before any Phase 3 has run.
Two trials, two weeks, opposite share reactions
Last Thursday: Moderna and Merck reported that a personalised cancer vaccine cut the risk of melanoma returning or proving fatal by 42%. Oncologists called it an important advance. Moderna fell as much as 25% and closed down about 18%.
This Monday: Oruka reported 61% complete skin clearance against 0% on placebo. The stock rose about 12%.
The medicines have nothing to do with it. The difference is what each share price already assumed.
- 📈 Moderna had risen more than 500% in 2026, much of it on the expectation that this trial would succeed. Success was therefore the minimum. A figure slightly below an earlier study was enough to trigger selling.
- 🔬 Oruka is a clinical-stage company whose drug has never been approved. Far less was assumed. Good data was genuinely new information, so the price moved up to reflect it.
The rule underneath both: a share price is a bet already placed. News moves it only to the extent it differs from what was expected. That is why "was this good?" is the wrong question and "was this better than assumed?" is the right one.
We have now watched this mechanism five times in two weeks: Netflix grew profit 49% and fell, Boeing won a six-year certification and moved half a percent, Spotify missed on earnings and rose 7%, Moderna succeeded and fell, and now Oruka succeeded and rose. One mechanism, five outcomes.
What could go wrong
- 🧪 Phase 2 is not Phase 3. Promising mid-stage results routinely fail to repeat in larger, longer trials. Oruka plans to start Phase 3 in the first half of 2027, and that is where the question gets answered.
- ⏳ Week 16 is a snapshot. It says nothing about whether the effect lasts. The company's 52-week data is due in December, and the once-yearly maintenance idea is being tested by re-randomising patients at Week 28.
- 💸 Clinical-stage biotech has no revenue. Companies at this stage fund themselves by issuing shares or raising debt, which can dilute existing holders. That risk sits alongside the science.
- 🎢 Small biotech is violently volatile. A 12% gain on good data is the same mechanism that produces a 50% fall on bad data. Position sizes that feel exciting here can be the ones that hurt most.
- 🏁 The competition is large and established. The IL-23 class already contains approved products from major pharmaceutical companies with sales forces, pricing power and patient relationships.
- 🏥 And the medicine is not available. It is investigational. Nothing here is medical advice, and anyone affected by psoriasis should speak to their own clinician rather than reading anything into a share price.
ORKA is an example to research, not a recommendation.
What should investors take from this?
Before any dated event, write down what you think the market expects. If you can't state it, you don't know what you're betting on, and the reaction will surprise you even when the outcome doesn't.
Three habits:
- 🔍 Check how far a share has already run. A stock up 500% needs a surprise, not a success. A stock nobody has priced for success can rise on ordinary good news.
- ⚖️ Respect binary risk. A single trial that can double or halve a company is not a position to size casually, whatever the story.
- 🧺 Remember you can own the sector instead. Healthcare and biotech funds spread single-trial risk across dozens of companies, which is the argument for diversified funds in one sentence.
Research healthcare and biotech on Nemo.money
- From $1. Fractional investing, in research-sized amounts.
- Zero commission on US stocks and ETFs.
- Nemes: curated themed collections to start from.
- 6% AER interest on uninvested cash, paid daily in USD.
FAQs
What did Oruka Therapeutics report?
Week 16 results from EVERLAST-B, a Phase 2b trial of ORKA-001 in 187 patients with moderate-to-severe plaque psoriasis. 61% of high-dose patients achieved complete skin clearance (PASI 100) against 0% on placebo, and 86% achieved 90% improvement. 39% of high-dose patients reported a treatment-emergent side effect against 43% on placebo, none serious.
Why did the stock rise?
The results were new information. Oruka is a clinical-stage company whose treatment has never been approved, so success was not already assumed in the share price. The stock rose about 12% to roughly $89 on Monday 26 October.
Is the treatment available?
No. ORKA-001 is investigational and not approved. The company plans to start Phase 3 trials in the first half of 2027 after discussions with regulators. Anyone affected by psoriasis should speak with their own clinician.
What happens next?
52-week data from the companion EVERLAST-A trial is expected in December 2026, results for a second candidate are expected in the first quarter of 2027, and Phase 3 is planned for the first half of 2027.
Can I invest in Oruka from the UAE?
Oruka Therapeutics trades on the Nasdaq under the ticker ORKA. On Nemo.money you can research and invest in eligible US-listed stocks and ETFs from $1 with zero commission, with uninvested cash earning 6% AER interest, paid daily in USD. ORKA is an example to research, not a recommendation, and clinical-stage biotech carries high risk. Your capital is at risk.
Nemo = Never Miss Out.
Stay informed. Stay ahead.
#Biotech #ORKA #ClinicalTrials #StockMarket #Investing #NemoMoney
Terms and conditions apply. This is not investment advice and not medical advice. Past performance is not indicative of future results. Your capital is at risk. See website for Risk Disclosure. Exinity ME Ltd (https://nemo.money) is regulated by ADGM's Financial Services Regulatory Authority.
